AstraZeneca in first COVID-19 vaccine deal with Chinese company

Shenzhen Kangtai Biological Products (300601.SZ) will produce AstraZeneca Plc’s (AZN.L) potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world’s most populous countries.